Frequency and severity of adverse events possibly, probably, or definitely related to lestaurtinib administration
. | No. patients (%) . | . | . | ||
|---|---|---|---|---|---|
. | Grades 1/2 . | Grades 3/4 . | Grade 5 . | ||
| Elevated alkaline phosphatase | 13 (45) | 0 | 0 | ||
| Anorexia/nausea | 8 (28) | 2 (7) | 0 | ||
| Diarrhea | 6 (21) | 2 (7) | 0 | ||
| Transaminitis | 7 (24) | 0 | 0 | ||
| Constipation | 5 (17) | 0 | 0 | ||
| Hyperbilirubinemia | 5 (17) | 0 | 0 | ||
| Vomiting | 5 (17) | 0 | 0 | ||
| Fatigue | 3 (10) | 1 (3) | 0 | ||
| Dyspepsia | 2 (7) | 1 (3) | 0 | ||
| Elevated creatinine | 3 (10) | 0 | 0 | ||
| Arthralgia/myalgia | 2 (7) | 0 | 0 | ||
| Dizziness | 2 (7) | 0 | 0 | ||
| GI hemorrhage | 2 (7) | 0 | 0 | ||
| Headache | 2 (7) | 0 | 0 | ||
| CNS hemorrhage | 0 | 0 | 1 (3) | ||
| Depressed level of consciousness | 0 | 1 (1) | 0 | ||
. | No. patients (%) . | . | . | ||
|---|---|---|---|---|---|
. | Grades 1/2 . | Grades 3/4 . | Grade 5 . | ||
| Elevated alkaline phosphatase | 13 (45) | 0 | 0 | ||
| Anorexia/nausea | 8 (28) | 2 (7) | 0 | ||
| Diarrhea | 6 (21) | 2 (7) | 0 | ||
| Transaminitis | 7 (24) | 0 | 0 | ||
| Constipation | 5 (17) | 0 | 0 | ||
| Hyperbilirubinemia | 5 (17) | 0 | 0 | ||
| Vomiting | 5 (17) | 0 | 0 | ||
| Fatigue | 3 (10) | 1 (3) | 0 | ||
| Dyspepsia | 2 (7) | 1 (3) | 0 | ||
| Elevated creatinine | 3 (10) | 0 | 0 | ||
| Arthralgia/myalgia | 2 (7) | 0 | 0 | ||
| Dizziness | 2 (7) | 0 | 0 | ||
| GI hemorrhage | 2 (7) | 0 | 0 | ||
| Headache | 2 (7) | 0 | 0 | ||
| CNS hemorrhage | 0 | 0 | 1 (3) | ||
| Depressed level of consciousness | 0 | 1 (1) | 0 | ||
GI indicates gastrointestinal; CNS, central nervous system.
Table shows all grades 1 to 2 toxicities that occurred in 2 or more patients, and all grades 3 to 5 toxicities.